ian relations and education at CryoLife. "The most important advantage is growing evidence of improved long-term survival over other valve replacement options. The procedure is also attractive because patients who undergo the procedure do not have to take long-term, blood-thinning medications after surgery. This is particularly appealing to women of child-bearing age and athletes."
"However, the Ross Procedure requires very specific surgical expertise to achieve predictable, long-lasting results, and The Ross Summit was created to foster data exchange to provide a well-rounded point of view in addition to offering critical procedural training."
A decellularized human pulmonary heart valve, CryoValve(R) SG, processed using CryoLife's SynerGraft(R) technology, was cleared by the FDA in February 2008 for use in cardiac reconstruction procedures, which includes the Ross Procedure.
Led by Professor Sir Magdi Yacoub, FRS, FRCS, of Imperial College's Heart Science Center in London in tandem with Dr. Northrup, the Ross Summit will have a faculty of more than 30 world-renowned cardiovascular surgeons, who will present clinical data on heart reconstruction surgery at their respective clinics. The summit includes two afternoons of hands-on instruction in the various techniques of cardiac reconstruction. A full faculty list and summit agenda can be found at www.TheRossSummit.org.
"The summit has doubled in attendance since our inaugural session in fall 2008," said Steven G. Anderson, chairman, president and CEO of CryoLife. "We're thrilled with the registration numbers to date and look forward to an informative, dynamic summit."
About CryoLife, Inc.
Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues
'/>"/>
SOURCE CryoLife, Inc. Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 4 Related biology technology :1.
ACD Completes the Second Closing of Series A Financing and Initiates Services for Biomarker Validation and Companion Diagnostic Development2.
NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine Candidate3.
avVaa World Health Care Products, Inc. Announces the completion of its first week of DRTV 120/60 second test commercials for Neuroskin(R) Psoriasis Relief4.
Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress5.
Encorium Announces Receipt of Letters from Nasdaq Regarding its Second Quarter 2009 Form 10-Q Filing6.
Encorium Reports Second Quarter 2009 Financial Results7.
Los Gatos Research Introduces Second Generation Liquid-Water Isotope Analyzer8.
Spherix Reports Second Quarter 2009 Earnings9.
Lotus Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results10.
NovaBay Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results11.
China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results